NCT04970212View on ClinicalTrials.gov

Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

September 24, 2021

Primary Completion Date

October 8, 2022

Study Completion Date

October 8, 2022

Conditions

Carcinoma, HepatocellularMetastatic Liver Cancer

Interventions

DEVICE

BioTraceIO Lite

The BioTraceIO software will analyze the ultrasound images, and provide the physician with an estimated tissue damage map.

Trial Locations (6)

44106

University Hospitals Cleveland, Cleveland

55905

Mayo Clinic, Rochester

77030

Houston Methodist Hospital, Houston

85054

Mayo Clinic, Phoenix

94305

Stanford Medicine, Stanford

02114

Massachusetts General Hospital, Boston

All Listed Sponsors

lead

Techsomed Medical Technologies LTD

INDUSTRY

NCT04970212 - Safety and Effectiveness of BioTraceIO Lite for Tissue Damage Assessment Following Liver Tissue Ablation Procedures | Biotech Hunter | Biotech Hunter